Maintenance therapy alone versus radiation plus maintenance for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial compares standard maintenance treatment versus adding focused radiation to remaining limited (oligometastatic) spots in the body after initial chemotherapy. It aims to see whether treating those limited spots with radiation can improve outcomes without unacceptable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years.
- Your lung cancer is non-small cell lung cancer confirmed by biopsy.
- After 4–6 cycles of standard chemotherapy or drug treatment, your cancer has not progressed.
- Your cancer is limited to 1–5 metastatic sites (spread), not counting the original lung tumor and nearby lymph nodes; you should not have more than 3 spots in one organ.
- You must have scans that show the limited metastatic spots are treatable with a high-dose, focused radiation plan (or you have already treated some spots, with no more than 5 total by study entry).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether high-precision radiation (SBRT) can improve outcomes for people with up to 5 small, stable metastases from certain cancers, compared to usual palliative care. It is for those whose disease is not growing after current chemotherapy.
This study is for people with solid tumors that have spread to a few spots (5 or fewer) in the body. It tests whether using a focused treatment like radiation or ablation on those spots can help control the cancer long-term.
This trial compares two types of radiation for people whose cancer has spread to a few new spots while on or after treatment. It tests whether a precise, high-dose radiation approach (stereotactic) works better than the usual palliative radiation for controlling these growing spots.
This trial tests whether adding local treatments like radiation or surgery to standard immunotherapy can help people with lung cancer that has spread to a few spots. It aims to see if this combination improves control of the disease.
This trial compares continuing drug therapy alone versus adding local treatments (surgery or radiation) for people with stage IV lung cancer that has responded to initial treatment but still has a few remaining spots (oligometastatic). The goal is to see if targeting those spots with local therapy helps control the cancer longer.
This trial tests whether giving a maintenance medication (pembrolizumab) after targeted radiation helps keep kidney cancer that has spread to a few spots (5 or fewer) from growing. You would receive radiation to each spot and then be randomly assigned to receive either the medication or a placebo (inactive substance) for up to about 2 years.
Hear when a new Oligometastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.